It’s Time For U.S. Companies To Embrace Lean Manufacturing

The U.S. manufacturing sector has seen a decline, with domestic producers’ market share for goods dropping to 66% in 2022 and productivity remaining stagnant since 2011. Manufacturers grapple with challenges ranging from supply chain disruptions to accessing cutting-edge production technology. However, lean manufacturing, rooted in employee engagement and data-driven approaches, emerges as a beacon of hope, with its potential to reverse this decline.

Research by Industry Reimagined 2030 highlights the effectiveness of lean manufacturing, but emphasizes the need for a modern adaptation and greater understanding among companies. Despite only a fraction of U.S. firms harnessing its benefits, lean manufacturing stands as a pivotal strategy that could rejuvenate the American manufacturing landscape.

In recent years, the concept of lean operations, known for its low-inventory and just-in-time approach, has faced challenges and scrutiny as unpredictable global events strained supply chains. As the business landscape has shifted, there has been a pivot towards resilience, with many companies favoring stockpiling inventory “just in case.” Now, as businesses grapple with the emergence of a new normal, the importance of efficiency is once again in the spotlight, bringing lean back into consideration.

However, a pressing concern arises from the United States’ diminishing expertise in operations management over the past few decades. With fewer universities offering specialized courses and an increasing number of executives lacking foundational knowledge in the field, the intricacies of operations management risk being oversimplified or misunderstood. This misapplication could be detrimental, as successful lean practices require a profound understanding of operations and stakeholder value. For a deeper dive into this topic and its complexities, Tyson Browning, Professor of Operations Management at Neeley School of Business at Texas Christian University, offers his view.

 

Tyson’s Thoughts

“Experts are always calling for more lean, no matter what the times. Over the past three years, though, the just-in-time, low-inventory, lean operation and supply chain model has been stressed, to say the least, to the point where lean has been questioned. Rather, resilience became the buzzword, and keeping inventory just in case was often the answer.

Now that operations are returning somewhat to normal, and as supply chains are reforming around a new normal, the question of productivity and efficiency is back, and lean practices are no doubt going to be part of the solution. Generally, though, over the past several decades, the United States has lost a lot of its operations management expertise. Many universities no longer have an operations management department or as many operations management courses—certainly not as many students. Many executives come from finance or other backgrounds where operations management is thought of as a bunch of details that can just be left to others, or something that one could obtain a better version of simply by writing a check. But as Elon Musk discovered trying to get the Tesla factory up to speed a few years ago, and as many others are learning now, as manufacturing is returning to the U.S., excellent operations management is not trivial or simple.

A particular danger is when naive managers apply lean practices willy-nilly or dogmatically without a deep understanding of their operations and how they provide value for their stakeholders. But done right, lean practices are a terrific contributor to improved operations, and hopefully our nation will benefit from using them appropriately going forward.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More